Aristoteles Giagounidis, Ghulam J. Mufti, Pierre Fenaux, Mikkael A. Sekeres, Jeffrey Szer, Uwe Platzbecker, Andrea Kuendgen, Gianluca Gaidano, Wieslaw Wiktor-Jedrzejczak, Kuolung Hu, Paul Woodard, Allen S. Yang and Hagop M. Kantarjian Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia Cancer 120
Article first published online: 4 APR 2014 | DOI: 10.1002/cncr.28663
Romiplostim increases platelet counts and decreases bleeding events and platelet transfusions in patients with low-risk/intermediate-1–risk myelodysplastic syndrome. The study drug has been stopped because of concerns regarding increased blast counts and progression to acute myeloid leukemia; survival and acute myeloid leukemia rates are similar, and follow-up is ongoing.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field